MAY 0 3 200 Application No.:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

10/647,801

Confirmation No.: 2351

Applicant:

Liotta et al.

Filed:

August 25, 2003

TC/A.AU.:

1621

Examiner:

Unassigned

Docket No.:

18085.105233 EMU 2010 CON

Customer No.:

20786

Title:

•

Sphingolipid Derivatives and Their Method of Use

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

Transmittal of Information Disclosure Statement

Sir:

The citation of information on the attached Form PTO-1449, "List of Art Cited by Applicant," is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each of the following references are being submitted as part of this Information Disclosure Statement: AC, AG, AN, AP, A1, AT, AU, AV, AW, AX, AY, AZ, AAA, BA, BB, BD, BE, BG, BK, BM, BN, BO, CC, CS, CT, CV, and DA. A copy of each of the remainder of the references was submitted for the parent application, U.S.S.N. 09/249,211, now issued as U.S. patent 6,610,835. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Because this Information Disclosure Statement is being submitted before the mailing of a first Office action on the merits as under 37 CFR §1.97(b)(3) the Applicant does not believe that any fees are due; however, the Commissioner is hereby authorized to charge any fees due or credit any overpayment to Deposit Account No. 11-0980.

Respectfully submitted,

Madeline I. Johnston, Esq.

Reg. No. 36,1/74

Date: April 29, 2004 King & Spalding, LLP

191 Peachtree Street, N.E., Atlanta, GA 30303 Office: (404)572-4600/ Fax: 404-572-5145

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in a box addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on April 29, 2004.

Tisha Hardrick

3437323_1.DOC

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO
ADEMOSTRATION DISCLOSURE

STATEMENT BY APPLICANT
(use as many sheets as necessary)

4

1 of

Sheet

	Complete if Known
Application Number	10/647,801
Filing Date	August 25, 2003
First Named Inventor	Liotta et al.
Group Art Unit	1621
Examiner Name	Unassigned
Attorney Docket Number	18085.105233 EMU 2010 CON

3437303 2

			U.	S. PATENT DOCUMENTS		
Examiner Initials *	Cite No. ¹	U.S. Patent Docum	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	5,103,002	A	Wieland	04-07-1992	
	AB	5,110,987	A	Liotta et al.	05-05-1992	
	AC	5,122,450	A	Feizi <i>et al</i> .	06-16-1992	
	AD	5,190,876	A	Merrill	03-02-1993	
	AE	5,232,837	A	Merrill et al.	08-03-1993	
	AF	5,430,169	A	Boumendjel et al.	06-04-1995	
	AG	5,440,012	A	Takei et al.	08-08-1995	
	AH	5,459,057	Α	Merrill et al.	10-07-1995	
	ΑI	5,463,092	Α	Kumar Raj et al.	10-31-1995	
	AJ	5,488,166	Α	Hudlicky	01-30-1996	
	AK	5,518,879	A	Merrill et al.	05-21-1996	
	AL	5,599,914	Α	Wiegand Herbert et al.	02-04-1997	
	AM	5,610,040	Α	Smeets et al.	03-11-1997	
_	AN	5,616,577	Α	Nambi et al.	04-01-1997	
	AO	5,635,536	A	Lyons	06-03-1997	
	AP	5,672,693	A	Kawahara	09-30-1997	
	AQ	5,780,441	Α	Higa et al.	07-14-1998	
	AR	5,910,425	Α	De Boer et al.	06-08-1999	
	AS	5,916,911	Α	Shayman et al.	06-29-1999	
	ΑT	6,010,733	A	Takemoto et al.	01-04-2000	
	AU	6,043,218	Α	Dix et al.	03-28-2000	
	AV	6,063,796	Α	Yang et al.	05-16-2000	
	AW	6,127,578	Α	Merrill et al.	10-03-2000	
	AX	6,610,835	B1	Liotta et al.	08-26-2003	

				FORE	ZIGN PATENT DOCUMENTS			
Examiner	Cite	For	eign Patent Do	cument	Name of Patentee or Applicant of	Date of	Pages, Columns, Lines,	
Initials *	No. 1	Office ³	Number k	Kind Code ² (if known)	Cited Document	Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	6
	AY	JP	1-93562			04-12-1989		П
	ΑZ	EP	0,556,962	Al	Orosz (Rich. Ged. Veg.Gy. RT)	08-25-1993		П
	AAA	EP	0,560,267	Al	Beaulieu (Bio-Mega; Boehringer)	09-15-1993		

Examiner	Date	
Signature	Considered	
Oignature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


	Complete if Known
Application Number	10/647,801
Filing Date	August 25, 2003
First Named Inventor	Liotta et al.
Group Art Unit	1621
Examiner Name	Unassigned
Attorney Docket Number	18085.105233 EMU 2010 CON
-	Filing Date First Named Inventor Group Art Unit Examiner Name

							343/303	
				FORE	EIGN PATENT DOCUMENTS			
Examiner	niner Cite	eign Patent Doc		Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, Lines, Where Relevant	Т	
Initials *	No. 1	Office ³		(if known) Cited Document	Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	6
	BA	EP	0,666,268	A1	Akimoto <i>et al</i> .	08-09-1995		Т
	BB	EP	0,675,112	A1	Hunt (Bristol-Myers Squibb)	10-04-1995		Τ
	BC	EP	0,821,068		Rohm & Haas	01-28-1998		Т
	BD	WO	87/02777	Al	Feizi et al. (Res. Corp. Ltd.)	05-07-1987		1
	BE	WO	95/29189	Al	Al-Obeidi et al. (Selectide Corp)	11-02-1995		1
	BF	WO	97/26891		Beiersdorf	07-31-1997		T
	BG	WO	97/47194	Al	Babu et al. (Biocryst Pharm.)	12-18-1997		\top
	BH	WO	97/10817		Univ. Michigan	03-27-1997		T

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examine r Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 6
术	BI	BENNUN et al., Infect. & Immun., 57:969-974 (1989).	П
*	BJ	BELL, R., et al. Cold Spr. Harbor Sym. Quant. Biol. 53:103 (1988).	
	BK	BUEHRER, B.M., and BELL, R.M., "Inhibition of sphingosine kinase in vitro J. Biol. Chem. 267(5):3154-3159 (February 15, 1992).	
*	BL	BUEHRER and BELL, Adv. Lipid Res. 6:59-67 (1993).	П
	BM	CARTER, S.R., et al., "Enzymatic sulfation of mucus glycoprotein in gastric mucosa," J. Blol. Chem., 263(24):11977-11964 (August 25, 1988).	
	BN	CROSSMAN, M.W., and HIRSCHBERG, C.B., "Biosynthesis of phytosphingosine by the rat," J. Biol. Chem, 252(16):5815-5819 (August 25, 1977).	П
	ВО	DESAI, K., et al., "Fumonisins and fumonisin analogs as inhibitors of ceramide synthase and inducers of apoptosis," <i>Biochem. Biophys. Acta</i> , 1585(2-3):188-192 (December 30, 2002).	
*	BP	FARKAS-HIMSLEY et al., Proc. Natl. Acad. Sci. (USA) 92:6996-7000 (1995).	П
X	BQ	HAKOMORI,, J. Biol. Chem. 265:18713-18716 (1990).	
-*	BR	HANNUN et al., J. Bio. Chem. 261:12604-12609 (1986).	
*	BS	HANNUN, J. Biol. Chem. 269:3125-3128 (1994).	
*	BT	HANNUN and OBEID, Trends Biochem. Sci. 20:73-77 (1995).	
*	BU	J. Urol., 155(5):653A, Abst. 1367 (1996).	
*	BV	JACEWICZ et al., J. Clin. Invest. 96:1328-1335 (1995).	
*	BW	JEFFERSON, A. and SCHULMAN, H., J. Biol. Chem. 263:15241 (1988).	

Examiner Signature	Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

1.440/DTO				Complete if Known	
1449/P1O			Application Number	10/647,801	
	N DICCL O	OT IDE	Filing Date	August 25, 2003	
			First Named Inventor	Liotta et al.	
EMENT	BY APPLIC	CANT	Group Art Unit	1621	
			Examiner Name	Unassigned	
3	of	4	Attorney Docket Number	18085.105233 EMU 2010 CON	
		RMATION DISCLOSEMENT BY APPLIC	RMATION DISCLOSURE EMENT BY APPLICANT	Application Number Filing Date First Named Inventor Group Art Unit Examiner Name	

_		343730.	<u> </u>
		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examine r Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 6
*	CA	KARLSSON, K. A., Chem. Phys. Lipids, 5:6-43 (1970).	
*	СВ	KAWAI, G., et al., "Stimulatory effect of certain plant sphingolipids on fruiting of Schizophyllum commune," J. of Biol. Chem., 261(2):779-784 (1986).	
	CC	KENNEDY, K.J., et al., "Asymmetric synthesis of non-natural homologues of lysine," Bioorg. Med. Chem. Lett., 7(14):1937-1940 (1997).	
*	CD	KEUSCH et al., Infect. & Immun. 63: 1138-1141 (1995).	\top
*	CE	KOLESNICK, Cell 77:325-328 (1994).	T
*	CF	MERRILL et al., Fungal Lipids (R. Prasad and M. Ghanoum, eds.), CRC Press, Boca Raton, FL (1995).	\top
*	CG	MERRILL and WANG, Methods Enzymol, 209:427-437 (1992).	1
*	CH	MERRILL et al., J. Biol. Chem. 261:3764-3769 (1986).	
*	CI	MERRILL & SWEELEY, "Sphingolipids: metabolism and cell signalling," New Comprehensive	T
个		Biochemistry: Biochemistry of Lipids, Lipoproteins, and Membranes, (Vance, D.E. & Vance, J.E., eds.), pp.	
1.		309-338, Elsevier Science, Amsterdam (1996).	
· *	CJ	MINN, A. J., et al., Blood 86: 1903-1910 (1995).	┸
*	CK	MINN, A. J., et al., Nature, 385: 353-357 (1997).	
- *	CL	MORRISON, Biochim. Biophys. Acta., 176:537-546 (1969).	\perp
*	CM	MUCHMORE, S. W., et al., Nature, 381: 335-341 (1996)	┸
*	CN	NILSSON, A., Biochim. Biophy. Acta. 164:575-584 (1968).	\perp
***	CO	Patent Abstracts of Japan, vol095, no. 002, (March 31, 1995).	┖
*	CP	PITTET, D., et al., J. Biol. Chem. 262:10072 (1987).	
*	CQ	ROBSON et al., J. Lipid Res. 35:2060-2068 (1994).	
*	CR	SCHMELZ et al., Journal of Nutrition. 124:702-712	
	CS	SCHMITZ, B., <i>et al.</i> , "Determination of structural elements of the L2/HNK-1 carbohydrate epitope required for its function," <i>Glycoconjugate J.</i> , 11(4):345-352 (1994).	
	СТ	SUZUKI, N., et al., "Farnesyltransferase inhibitors induce Cytochrome C release," Proc. Natl. Acad. Sci.	t
		USA, 95:15356-15361 (December 1998).	1
*	CU	THOMPSON, et al., Biochem. Pharmacol. 56: 591-597, 1998.	T
	CV	WADDELL, S.T., et al., "Chimeric azalides with functionalized western portions," Heterocycles,	\dagger
		43(11):2325 (1996).	
*	CW	WELLS, G. B. and LESTER, R.L., J. Biol. Chem., 258:10200-10203 (1983).	T
*	CX	WILSON et al., J. Biol. Chem. 261:12616-12623 (1986).	T
*	CY	WINICOV, I. and GERSHENGORN, M., J. Biol. Chem. 263:12179 (1988).	T

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	1440/070			Complete if Known		
Submitted for fo	m 1449/P10			Application Number	10/647,801	
INTE	ORMATION I	MCCI O	CUDE	Filing Date	August 25, 2003	
				First Named Inventor Liotta et al.		
SIA	TEMENT BY	APPLI	CANI	Group Art Unit	1621	
				Examiner Name	Unassigned	
Sheet	4	of	4	Attorney Docket Number	18085.105233 EMU 2010 CON	

3437303_2

457				_		
		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
	Examine r Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ₆		
		DA	WIPF, P., and HENNINGER, T.C., "Solid-phase synthesis of peptide mimetics with (E)-alkene amide bond replacements derived from alkenylaziridines," J. Org. Chem., 62(6):1586-1587 (1997).			
ı	4	DB	WU et al., J. Biol. Chem. 268:13830-13837 (1993).			

3437303 1

<u> </u>		
Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applica	tion of:)
	Liotta <i>et al</i> .)
Serial No.:	10/647,801) Art Unit: 2351
Filing Date:	August 25, 2003) Examiner: Unassigned)

Title: Sphingolipid Derivatives and Their Method of Use

APPOINTMENT OF ASSOCIATE ATTORNEY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Please recognize the following registered patent practitioners as Associate Attorneys to prosecute the above-entitled application and transact all business in the Patent and Trademark Office connected therewith: W. Scott Petty-35,645; Madeline I. Johnston-36,174; Clark G. Sullivan-36,942; Holmes J. Hawkins-38,913; Steven P. Wigmore-40,447; Michael S. Pavento-42,985; Shane A. Nichols-43,836; Bill Isaacs-44,165; Rebecca J. Kaufman-44,819; Charles Peeler-45,004; Stephanie D. Adams-47,378; Bob Neufeld-48,394; James M. Hannon-48,565; Charles Thorpe, Jr -48,782; Susanne Hollinger-51,811; Natasha Horne Moffitt-53,340; Monte R. Rhodes-54,396; Michael L. Wach-54,517; Brent R. Bellows-54,709; James J.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on Uni 29, 2007

Tisha Hardrick

Mayberry-P-55,438; all of the firm of King & Spalding, LLP, 45th Floor, 191 Peachtree Street, N.E., Atlanta, Georgia 30303, and address all future communication to the firm.

Respectfully submitted,

Sherry M. Knowles, Esq.

Reg. No. 33,052

King & Spalding, LLP 45th Floor 191 Peachtree Street, N.E. Atlanta, Georgia 30303 404.572.4600

K&S Docket: 04342.105046 UGA 665 CON1